First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 184 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... February 14, 2023 NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials April 23, 2020 Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma December 10, 2025 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan October 19, 2022 Load more HOT NEWS How I Coped With My Own Cancer Diagnoses As an Oncologist Partnership in a pandemic: how Credit Suisse delivered an incredible Charity... Cancer Researchers Bring Tools, Experience to COVID-19 Studies Black In Cancer – That Cancer Conversation
